Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

Etxeberria I, Bolaños E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sánchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, Ochoa MC, Labiano S, Garasa S, Rodriguez I, Vidal A, Mancheño U, Hervás-Stubbs S, Azpilikueta A, Otano I, Aznar MA, Sanmamed MF, Inogés S, Berraondo P, Teijeira Á, Melero I.

Cancer Cell. 2019 Nov 6. pii: S1535-6108(19)30480-5. doi: 10.1016/j.ccell.2019.10.006. [Epub ahead of print]

PMID:
31761658
2.

Immune Desertic Landscapes in Hepatocellular Carcinoma Shaped by β-Catenin Activation.

Berraondo P, Ochoa MC, Olivera I, Melero I.

Cancer Discov. 2019 Aug;9(8):1003-1005. doi: 10.1158/2159-8290.CD-19-0696.

PMID:
31371324
3.

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity.

Alvarez M, Otano I, Minute L, Ochoa MC, Perez-Ruiz E, Melero I, Berraondo P.

Cell Stress. 2019 Jun 27;3(7):236-239. doi: 10.15698/cst2019.07.193.

4.

Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells.

Ochoa MC, Perez-Ruiz E, Minute L, Oñate C, Perez G, Rodriguez I, Zabaleta A, Alignani D, Fernandez-Sendin M, Lopez A, Muntasell A, Sanmamed MF, Paiva B, Lopez-Botet M, Berraondo P, Melero I.

Oncoimmunology. 2019 Apr 13;8(7):1599636. doi: 10.1080/2162402X.2019.1599636. eCollection 2019.

PMID:
31143521
5.

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.

Perez-Ruiz E, Minute L, Otano I, Alvarez M, Ochoa MC, Belsue V, de Andrea C, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Llacer C, Alvarez M, de Luque V, Molina C, Teijeira A, Berraondo P, Melero I.

Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.

PMID:
31043740
6.

Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.

Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Review.

7.

Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Ochoa MC, Minute L, López A, Pérez-Ruiz E, Gomar C, Vasquez M, Inoges S, Etxeberria I, Rodriguez I, Garasa S, Mayer JA, Wirtz P, Melero I, Berraondo P.

Oncoimmunology. 2017 Nov 13;7(2):e1393597. doi: 10.1080/2162402X.2017.1393597. eCollection 2018.

8.

In-silico gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer.

Pey J, San José-Eneriz E, Ochoa MC, Apaolaza I, de Atauri P, Rubio A, Cendoya X, Miranda E, Garate L, Cascante M, Carracedo A, Agirre X, Prosper F, Planes FJ.

Sci Rep. 2017 Oct 30;7(1):14358. doi: 10.1038/s41598-017-14067-8.

9.

Targeting NK-cell checkpoints for cancer immunotherapy.

Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I.

Curr Opin Immunol. 2017 Apr;45:73-81. doi: 10.1016/j.coi.2017.01.003. Epub 2017 Feb 23. Review.

PMID:
28236750
10.

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.

Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inogés S, Melero I, Berraondo P.

Immunol Cell Biol. 2017 Apr;95(4):347-355. doi: 10.1038/icb.2017.6. Epub 2017 Feb 21. Review.

PMID:
28138156
11.

Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.

Berraondo P, Ochoa MC, Rodriguez-Ruiz ME, Minute L, Lasarte JJ, Melero I.

Cancer Res. 2016 May 15;76(10):2863-7. doi: 10.1158/0008-5472.CAN-15-3279. Epub 2016 May 2.

12.

Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.

Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheño U, Casales E, Riezu-Boj JI, Ruiz-Guillen M, Ochoa MC, Sanmamed MF, Thieblemont N, Smerdou C, Hervas-Stubbs S.

Cancer Res. 2015 Feb 1;75(3):497-507. doi: 10.1158/0008-5472.CAN-13-3356. Epub 2014 Dec 19.

13.

Sugar-sweetened carbonated beverage consumption and childhood/adolescent obesity: a case-control study.

Martin-Calvo N, Martínez-González MA, Bes-Rastrollo M, Gea A, Ochoa MC, Marti A; GENOI Members.

Public Health Nutr. 2014 Oct;17(10):2185-93. doi: 10.1017/S136898001300356X. Epub 2014 Jan 31.

PMID:
24485091
14.

Innate functions of immunoglobulin M lessen liver gene transfer with helper-dependent adenovirus.

Unzu C, Melero I, Morales-Kastresana A, Sampedro A, Serrano-Mendioroz I, Azpilikueta A, Ochoa MC, Dubrot J, Martínez-Ansó E, Fontanellas A.

PLoS One. 2014 Jan 21;9(1):e85432. doi: 10.1371/journal.pone.0085432. eCollection 2014.

15.

[The association between dietary macronutrients intake and obesity among children and adolescents; a case-control study].

Martín-Calvo N, Ochoa MC, Marti A, Martínez-González MÁ.

Nutr Hosp. 2013 Sep-Oct;28(5):1515-22. doi: 10.3305/nh.2013.28.5.6678. Spanish.

16.

High-density lipoproteins delivering interleukin-15.

Ochoa MC, Melero I, Berraondo P.

Oncoimmunology. 2013 Apr 1;2(4):e23410.

17.

Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy.

Ochoa MC, Fioravanti J, Duitman EH, Medina-Echeverz J, Palazon A, Arina A, Dubrot J, Alfaro C, Morales-Kastresana A, Murillo O, Hervas-Stubbs S, Prieto J, Berraondo P, Melero I.

PLoS One. 2012;7(12):e52370. doi: 10.1371/journal.pone.0052370. Epub 2012 Dec 21.

18.

The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies.

Mazzolini G, Ochoa MC, Morales-Kastresana A, Sanmamed MF, Melero I.

Immunotherapy. 2012 Nov;4(11):1081-5. doi: 10.2217/imt.12.99. No abstract available.

PMID:
23194355
19.

Interleukin-15 in gene therapy of cancer.

Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I.

Curr Gene Ther. 2013 Feb;13(1):15-30. Review.

PMID:
23157547
20.

Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.

Cancer Res. 2013 Jan 1;73(1):139-49. doi: 10.1158/0008-5472.CAN-12-2660. Epub 2012 Nov 13.

21.

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.

Hervas-Stubbs S, Mancheño U, Riezu-Boj JI, Larraga A, Ochoa MC, Alignani D, Alfaro C, Morales-Kastresana A, Gonzalez I, Larrea E, Pircher H, Le Bon A, Lopez-Picazo JM, Martín-Algarra S, Prieto J, Melero I.

J Immunol. 2012 Oct 1;189(7):3299-310. Epub 2012 Aug 27.

22.

Dietary fatty acid distribution modifies obesity risk linked to the rs9939609 polymorphism of the fat mass and obesity-associated gene in a Spanish case-control study of children.

Moleres A, Ochoa MC, Rendo-Urteaga T, Martínez-González MA, Azcona San Julián MC, Martínez JA, Marti A; GENOI.

Br J Nutr. 2012 Feb;107(4):533-8. doi: 10.1017/S0007114511003424. Epub 2011 Jul 29.

23.

International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010.

Ochoa MC, Hervas-Stubbs S, Palazon A, Martinez-Forero I, Berraondo P, Sarobe P, Melcher A, Melero I.

Cancer Immunol Immunother. 2011 May;60(5):753-6. doi: 10.1007/s00262-011-1000-z. Epub 2011 Mar 5. No abstract available.

PMID:
21380561
24.

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, Ochoa-Callejero L, Martínez A, Luque A, Dinchuk J, Rouzaut A, Jure-Kunkel M, Melero I.

Cancer Res. 2011 Feb 1;71(3):801-11. doi: 10.1158/0008-5472.CAN-10-1733. Epub 2011 Jan 25.

25.

Dietary total antioxidant capacity and obesity in children and adolescents.

Puchau B, Ochoa MC, Zulet MA, Marti A, Martínez JA, Members G.

Int J Food Sci Nutr. 2010 Nov;61(7):713-21. doi: 10.3109/09637481003757860.

26.

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.

Dubrot J, Milheiro F, Alfaro C, Palazón A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervás-Stubbs S, Prieto J, Jure-Kunkel M, Chen L, Melero I.

Cancer Immunol Immunother. 2010 Aug;59(8):1223-33. doi: 10.1007/s00262-010-0846-9. Epub 2010 Mar 25.

PMID:
20336294
27.

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

Dubrot J, Palazón A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, Hervás-Stubbs S, Melero I.

Int J Cancer. 2011 Jan 1;128(1):105-18. doi: 10.1002/ijc.25333.

28.

Proliferating NK cells in response to IL-15 do not upregulate surface B220 in vivo.

Murillo O, Ochoa MC, Arina A, Gabari I, Dubrot J, Hervas-Stubbs S, Melero I.

Gene Ther. 2010 May;17(5):687-9. doi: 10.1038/gt.2009.139. Epub 2009 Oct 29. No abstract available.

PMID:
19865177
29.

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.

Murillo O, Dubrot J, Palazón A, Arina A, Azpilikueta A, Alfaro C, Solano S, Ochoa MC, Berasain C, Gabari I, Pérez-Gracia JL, Berraondo P, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2009 Sep;39(9):2424-36. doi: 10.1002/eji.200838958.

30.

G allele of the -930A>G polymorphism of the CYBA gene is associated with insulin resistance in obese subjects.

Ochoa MC, Razquin C, Zalba G, Martínez-González MA, Martínez JA, Marti A.

J Physiol Biochem. 2008 Jun;64(2):127-33.

PMID:
19043982
31.

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma.

Murillo O, Arina A, Hervas-Stubbs S, Gupta A, McCluskey B, Dubrot J, Palazón A, Azpilikueta A, Ochoa MC, Alfaro C, Solano S, Pérez-Gracia JL, Oyajobi BO, Melero I.

Clin Cancer Res. 2008 Nov 1;14(21):6895-906. doi: 10.1158/1078-0432.CCR-08-0285.

32.

Treatment of obesity in children and adolescents. How nutrition can work?

Moreno LA, Ochoa MC, Wärnberg J, Marti A, Martínez JA, Marcos A.

Int J Pediatr Obes. 2008;3 Suppl 1:72-7. doi: 10.1080/17477160801897158. Review.

PMID:
18278636
33.

TV watching modifies obesity risk linked to the 27Glu polymorphism of the ADRB2 gene in girls.

Ochoa MC, Moreno-Aliaga MJ, Martínez-González MA, Martínez JA, Marti A; GENOI Members.

Int J Pediatr Obes. 2006;1(2):83-8.

34.

Association between obesity and insulin resistance with UCP2-UCP3 gene variants in Spanish children and adolescents.

Ochoa MC, Santos JL, Azcona C, Moreno-Aliaga MJ, Martínez-González MA, Martínez JA, Marti A; GENOI Members.

Mol Genet Metab. 2007 Dec;92(4):351-8. Epub 2007 Sep 17.

PMID:
17870627
35.

A novel mutation Thr162Arg of the melanocortin 4 receptor gene in a Spanish children and adolescent population.

Ochoa MC, Azcona C, Biebermann H, Brumm H, Razquin C, Wermter AK, Martínez JA, Hebebrand J, Hinney A, Moreno-Aliaga MJ, Marti A, Patiño A, Chueca M, Oyarzabal M, Pelach R; Grupo de Estudio Navarro de la Obesidad Infantil (GENOI).

Clin Endocrinol (Oxf). 2007 May;66(5):652-8.

36.

Predictor factors for childhood obesity in a Spanish case-control study.

Ochoa MC, Moreno-Aliaga MJ, Martínez-González MA, Martínez JA, Marti A; GENOI Members.

Nutrition. 2007 May;23(5):379-84. Epub 2007 Apr 3.

PMID:
17408922
37.

Meta-analysis on the effect of the N363S polymorphism of the glucocorticoid receptor gene (GRL) on human obesity.

Marti A, Ochoa MC, Sánchez-Villegas A, Martínez JA, Martínez-González MA, Hebebrand J, Hinney A, Vedder H.

BMC Med Genet. 2006 May 25;7:50.

38.

[Influence of the -866G/A polymorphism of the UCP2 gene on an obese pediatric population].

Zurbano R, Ochoa MC, Moreno-Aliaga MJ, Martínez JA, Marti A; Grupo de Estudio Navarro de la obesidad infantil.

Nutr Hosp. 2006 Jan-Feb;21(1):52-6. Spanish.

PMID:
16562813
39.
40.

Gene-gene interaction between PPAR gamma 2 and ADR beta 3 increases obesity risk in children and adolescents.

Ochoa MC, Marti A, Azcona C, Chueca M, Oyarzábal M, Pelach R, Patiño A, Moreno-Aliaga MJ, Martínez-González MA, Martínez JA; Groupo de Estudio Navarro de Obesidad Infantil (GENOI).

Int J Obes Relat Metab Disord. 2004 Nov;28 Suppl 3:S37-41.

PMID:
15543217
41.

Chronopharmacokinetics and calcium in the prevention of gentamicin-induced nephrotoxicity in rabbits.

Perez de la Cruz MJ, Cadórniga R, Ochoa MC, Albarran I, Herrero-Vanrell R, Pastoriza P.

Biopharm Drug Dispos. 1998 Sep;19(6):407-12.

PMID:
9737822
42.

Effect of the anticonvulsant U-54494A on cortical neuron excitability: comparison to the kappa agonist U-50488H.

Ochoa MC, Vogelsang GD, Lum JT, VonVoigtlander PF, Piercey MF.

Life Sci. 1992;50(17):1225-33.

PMID:
1349150
43.

Preliminary pharmacokinetics of a new pyridopyrimidine derivative.

Pérez MJ, Roch MJ, Ochoa MC.

Arzneimittelforschung. 1991 Jun;41(6):640-4.

PMID:
1930354
44.

New 5H-[1,3]thiazolo[3,2-a]pyrido[3,2-e]pyrimidine derivatives as diuretics.

Monge A, Martinez-Merino V, Sanmartin C, Ochoa MC, Fernandez-Alvarez E.

Arzneimittelforschung. 1990 Dec;40(12):1349-52.

PMID:
2095131
45.

Diuretic and hypotensive activities of 4-anilino derivatives of 2-methylthiopyrido[2,3-d]pyrimidines.

Monge A, Martinez-Merino V, Sanmartin C, Fernandez FJ, Ochoa MC, Bellver C, Artigas P.

Arzneimittelforschung. 1990 Nov;40(11):1230-3.

PMID:
2085335
46.

U-54494A: a unique anticonvulsant related to kappa opioid agonists.

VonVoigtlander PF, Hall ED, Ochoa MC, Lewis RA, Triezenberg HJ.

J Pharmacol Exp Ther. 1987 Nov;243(2):542-7.

PMID:
2824750
47.

Biochemical and functional interactions of a selective kappa opioid agonist with calcium.

VonVoigtlander PF, Ochoa MC, Lewis RA.

Adv Exp Med Biol. 1987;221:345-55.

PMID:
2829584
48.

Effects of the administration of artroglobina suppositories in healthy volunteers.

Ochoa MC, Fau R, Molina V, Vázquez A.

Int J Clin Pharmacol Biopharm. 1979 Dec;17(12):471-5.

PMID:
43295

Supplemental Content

Loading ...
Support Center